Recently,

the FOF Research Center Special List was grandly unveiled,

and Efung Capital was honored with:

2026 Top 30 Best Investment Institutions in the Healthcare Sector

2026 Top 50 Best VC Fund Returns

Efung Capital CEO Zhu Pai was honored with:

2026 Top 20 Best Investors in the Healthcare Sector.

In 2026, the equity investment industry is ushering in a year of "rebound." In this year's Government Work Report, venture capital was once again "strongly supported" — under the section "Cultivating and Expanding Emerging Industries and Future-Oriented Industries," the report proposed: efficiently utilizing the national venture capital guiding fund, vigorously developing venture capital and angel investment, with government investment funds taking the lead in being patient capital, and promoting more startups to grow into technology-leading enterprises at an accelerated pace. In addition, under the section "Vigorously Developing the Green and Low-Carbon Economy," the report proposed the establishment of a national low-carbon transition fund.

Currently, the equity investment industry is intensifying its focus on early-stage, small-scale, long-term, and hard-tech investments, using patient capital to nurture technological innovation among more enterprises. Against this backdrop, the FOF Research Center has released its 2026 Special List based on existing data support and research analysis, aiming to encourage outstanding institutions and talent in the private equity FOF and fund industries, and to promote the healthy development of the equity investment sector.

Looking ahead, Efung Capital will continue to adhere to its investment philosophy of "investing early, investing small, investing long-term, and investing in hard tech." With professional judgment and long-termist conviction, we are committed to helping China's technological innovation transition from "keeping pace" to "taking the lead," contributing Efung Capital's strength to the development of new quality productive forces.

【Disclaimer】

This article reflects solely the views of the Company based on currently available public information and data provided by its portfolio companies. It does not constitute any investment advice, medical advice, or a guarantee of any particular enterprise's performance. Investments carry risks and should be made with caution. Readers are advised to make independent judgments based on publicly available information. Unauthorized reproduction or commercial use is prohibited.